The North America medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
North America Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of North America medication-assisted treatment (MAT) are:
The rise in the population receiving medication-assisted treatment (MAT)
Availability of reimbursement for medication-assisted treatment (MAT)
Market Players:
Some of the major players operating in the North America medication-assisted treatment (MAT) market are:
Indivior PLC
Orexo US Inc (a subsidiary of Orexo AB)
Recovery Centers of America
Alkermes
Sun Pharmaceutical Industries Ltd.
Purdue Pharma L.P.
Taj Pharmaceuticals Limited
Lannett
Hikma Pharmaceuticals PLC
Pfizer Inc.
Pinnacle Treatment Center
American Addiction Centers
Adamis Pharmaceuticals Corporation
Glenmark Pharmaceutical Inc.
Viatris Inc.
Mallinckrodt
Alvogen
VistaPharm, Inc.
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC.
Titan Pharmaceuticals, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 49
- 1.1 OBJECTIVES OF THE STUDY 49
- 1.2 MARKET DEFINITION 49
- 1.3 OVERVIEW OF NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET 49
- 1.4 CURRENCY AND PRICING 52
- 1.5 LIMITATIONS 52
- 1.6 MARKETS COVERED 53
2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION 57
- 2.1 MARKETS COVERED 57
- 2.2 GEOGRAPHICAL SCOPE 58
- 2.3 YEARS CONSIDERED FOR THE STUDY 59
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 60
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
- 2.6 MULTIVARIATE MODELLING 64
- 2.7 PRODUCT SEGMENT LIFELINE CURVE 64
- 2.8 DBMR MARKET POSITION GRID 65
- 2.9 VENDOR SHARE ANALYSIS 67
- 2.10 MARKET END USER COVERAGE GRID 68
- 2.11 SECONDARY SOURCES 69
3 EXECUTIVE SUMMARY 70
4 PREMIUM INSIGHTS 74
- 4.1 EPIDEMIOLOGY 75
- 4.2 PESTEL 76
- 4.3 PORTER'S FIVE FORCES MODEL 77
- 4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021) 78
- 4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021) 78
- 4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021) 79
- 4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021) 79
- 4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET 80
5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS 81
6 MARKET OVERVIEW 84
- 6.1 DRIVERS 86
- 6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS 86
- 6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 87
- 6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT) 87
- 6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT) 88
- 6.2 RESTRAINTS 89
- 6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT) 89
- 6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT) 89
- 6.2.3 RISE IN PRODUCT RECALLS 89
- 6.3 OPPORTUNITIES 90
- 6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 90
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE 91
- 6.4 CHALLENGES 91
- 6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT 91
- 6.4.2 STRINGENT REGULATIONS 92
- 6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT) 93
7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE 94
- 7.1 OVERVIEW 95
- 7.2 MEDICATION 98
- 7.2.1 OPIOID DEPENDENCY MEDICATION 99
- 7.2.1.1 BUPRENORPHINE AND NALOXONE 99
- 7.2.1.2 BUPRENORPHINE 99
- 7.2.1.3 METHADONE 99
- 7.2.1.4 NALTREXONE 100
- 7.2.2 ALCOHOL USE DISORDER MEDICATIONS 100
- 7.2.2.1 NALTREXONE 100
- 7.2.2.2 DISULFIRAM 100
- 7.2.2.3 ACAMPROSATE 100
- 7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION 100
- 7.3 THERAPY 101
- 7.3.1 BEHAVIORAL THERAPY 102
- 7.3.2 EDUCATIONAL THERAPY 102
- 7.3.3 COUNSELLING 102
- 7.3.4 VOCATIONAL THERAPY 102
- 7.3.5 OTHERS 103
8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS 104
- 8.1 OVERVIEW 105
- 8.2 BUPRENORPHINE AND NALOXONE 108
- 8.3 NALTREXONE 108
- 8.4 BUPRENORPHINE 110
- 8.5 METHADONE 110
- 8.6 NALOXONE 111
- 8.7 DISULFIRAM 112
- 8.8 ACAMPROSATE 113
9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE 114
- 9.1 OVERVIEW 115
- 9.2 GENERICS 118
- 9.3 BRANDED 118
- 9.3.1 SUBOXONE 119
- 9.3.2 VIVITROL 119
- 9.3.3 BUTRANS 119
- 9.3.4 ZUBSOLV 120
- 9.3.5 PROBUPHINE 120
- 9.3.6 OTHERS 120
10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM 121
- 10.1 OVERVIEW 122
- 10.2 IMMEDIATE RELEASE 125
- 10.3 EXTENDED RELEASE 125
11 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION 127
- 11.1 OVERVIEW 128
- 11.2 ORAL 131
- 11.2.1 TABLET 132
- 11.2.2 SUBLINGUAL FILM 132
- 11.2.3 OTHERS 132
- 11.3 PARENTERAL 132
- 11.3.1 SOLUTION 133
- 11.3.2 SUSPENSION 133
- 11.4 OTHERS 134
12 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE 135
- 12.1 OVERVIEW 136
- 12.2 ADULTS 139
- 12.3 TEENAGE 139
13 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER 141
- 13.1 OVERVIEW 142
- 13.2 REHABILITATION CLINICS 145
- 13.3 HOSPITALS 145
- 13.4 SPECIALTY CENTERS 146
- 13.5 HOMECARE 147
- 13.6 OTHERS 148
14 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL 149
- 14.1 OVERVIEW 150
- 14.2 HOSPITAL PHARMACY 153
- 14.3 DIRECT TENDER 153
- 14.4 RETAIL PHARMACY 154
- 14.5 ONLINE PHARMACY 155
- 14.6 OTHERS 156
15 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION 157
- 15.1 NORTH AMERICA 158
- 15.1.1 U.S. 168
- 15.1.2 CANADA 173
- 15.1.3 MEXICO 178
16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE 183
- 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183
17 SWOT ANALYSIS 184
18 COMPANY PROFILE 185
- 18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021) 185
- 18.1.1 COMPANY SNAPSHOT 185
- 18.1.2 REVENUE ANALYSIS 186
- 18.1.3 COMPANY SHARE ANALYSIS 186
- 18.1.4 PRODUCT PORTFOLIO 186
- 18.1.5 RECENT DEVELOPMENTS 187
- 18.2 INDIVOR PLC (2021) 188
- 18.2.1 COMPANY SNAPSHOT 188
- 18.2.2 REVENUE ANALYSIS 188
- 18.2.3 COMPANY SHARE ANALYSIS 189
- 18.2.4 PRODUCT PORTFOLIO 189
- 18.2.5 RECENT DEVELOPMENTS 190
- 18.3 VIATRIS INC (2021) 191
- 18.3.1 COMPANY SNAPSHOT 191
- 18.3.2 REVENUE ANALYSIS 191
- 18.3.3 COMPANY SHARE ANALYSIS 192
- 18.3.4 PRODUCT PORTFOLIO 192
- 18.3.5 RECENT DEVELOPMENTS 192
- 18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021) 193
- 18.4.1 COMPANY SNAPSHOT 193
- 18.4.2 REVENUE ANALYSIS 193
- 18.4.3 COMPANY SHARE ANALYSIS 194
- 18.4.4 PRODUCT PORTFOLIO 194
- 18.4.5 RECENT DEVELOPMENTS 194
- 18.5 ALKERMES (2021) 195
- 18.5.1 COMPANY SNAPSHOT 195
- 18.5.2 REVENUE ANALYSIS 195
- 18.5.3 COMPANY SHARE ANALYSIS 196
- 18.5.4 PRODUCT PORTFOLIO 196
- 18.5.5 RECENT DEVELOPMENTS 197
- 18.6 PURDUE PHARMA L.P. (2021) 198
- 18.6.1 COMPANY SNAPSHOT 198
- 18.6.2 PRODUCT PORTFOLIO 198
- 18.6.3 RECENT DEVELOPMENTS 198
- 18.7 PFIZER (2021) 199
- 18.7.1 COMPANY SNAPSHOT 199
- 18.7.2 REVENUE ANALYSIS 199
- 18.7.3 PRODUCT PORTFOLIO 200
- 18.7.4 RECENT DEVELOPMENTS 200
- 18.8 GLENMARK PHARMACEUTICAL INC (2021) 201
- 18.8.1 COMPANY SNAPSHOT 201
- 18.8.2 REVENUE ANALYSIS 201
- 18.8.3 PRODUCT PORTFOLIO 202
- 18.8.4 RECENT DEVELOPMENTS 202
- 18.9 DR. REDDY'S LABORATORIES LTD (2021) 203
- 18.9.1 COMPANY SNAPSHOT 203
- 18.9.2 REVENUE ANALYSIS 203
- 18.9.3 PRODUCT PORTFOLIO 204
- 18.9.4 RECENT DEVELOPMENTS 204
- 18.10 ALVOGEN (2021) 205
- 18.10.1 COMPANY SNAPSHOT 205
- 18.10.2 PRODUCT PORTFOLIO 205
- 18.10.3 RECENT DEVELOPMENTS 205
- 18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021) 206
- 18.11.1 COMPANY SNAPSHOT 206
- 18.11.2 REVENUE ANALYSIS 206
- 18.11.3 PRODUCT PORTFOLIO 207
- 18.11.4 RECENT DEVELOPMENTS 207
- 18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS) 208
- 18.12.1 COMPANY SNAPSHOT 208
- 18.12.2 PRODUCT PORTFOLIO 208
- 18.12.3 RECENT DEVELOPMENTS 209
- 18.13 AMNEAL PHARMACEUTICALS LLC (2021) 210
- 18.13.1 COMPANY SNAPSHOT 210
- 18.13.2 REVENUE ANALYSIS 210
- 18.13.3 PRODUCT PORTFOLIO 211
- 18.13.4 RECENT DEVELOPMENTS 211
- 18.14 AMERICAN ADDICTION CENTERS (2021) 212
- 18.14.1 COMPANY SNAPSHOT 212
- 18.14.2 PRODUCT PORTFOLIO 212
- 18.14.3 RECENT DEVELOPMENTS 212
- 18.15 HIKMA PHARMACEUTICALS PLC (2021) 213
- 18.15.1 COMPANY SNAPSHOT 213
- 18.15.2 REVENUE ANALYSIS 213
- 18.15.3 PRODUCT PORTFOLIO 214
- 18.15.4 RECENT DEVELOPMENTS 214
- 18.16 LANNETT (2021) 215
- 18.16.1 COMPANY SNAPSHOT 215
- 18.16.2 REVENUE ANALYSIS 215
- 18.16.3 PRODUCT PORTFOLIO 216
- 18.16.4 RECENT DEVELOPMENT 216
- 18.17 MALLINCKRODT (2021) 217
- 18.17.1 COMPANY SNAPSHOT 217
- 18.17.2 REVENUE ANALYSIS 217
- 18.17.3 PRODUCT PORTFOLIO 218
- 18.17.4 RECENT DEVELOPMENT 218
- 18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021) 219
- 18.18.1 COMPANY SNAPSHOT 219
- 18.18.2 REVENUE ANALYSIS 219
- 18.18.3 PRODUCT PORTFOLIO 220
- 18.18.4 RECENT DEVELOPMENT 220
- 18.19 PINNACLE TREATMENT CENTERS 221
- 18.19.1 COMPANY SNAPSHOT 221
- 18.19.2 PRODUCT PORTFOLIO 221
- 18.19.3 RECENT DEVELOPMENT 221
- 18.20 RECOVERY CENTERS OF AMERICA 222
- 18.20.1 COMPANY SNAPSHOT 222
- 18.20.2 PRODUCT PORTFOLIO 222
- 18.20.3 RECENT DEVELOPMENTS 223
- 18.21 TAJ PHARMACEUTICALS LIMITED 224
- 18.21.1 COMPANY SNAPSHOT 224
- 18.21.2 PRODUCT PORTFOLIO 224
- 18.21.3 RECENT DEVELOPMENTS 224
- 18.22 TITAN PHARMACEUTICALS (2021) 225
- 18.22.1 COMPANY SNAPSHOT 225
- 18.22.2 REVENUE ANALYSIS 225
- 18.22.3 PRODUCT PORTFOLIO 226
- 18.22.4 RECENT DEVELOPMENTS 226
- 18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021)) 227
- 18.23.1 COMPANY SNAPSHOT 227
- 18.23.2 PRODUCT PORTFOLIO 227
- 18.23.3 RECENT DEVELOPMENTS 227
19 QUESTIONNAIRE 228
20 RELATED REPORTS 232